Get started
Author

N. Chen

Abstract PD10-02: I- SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients with stage 2/3 HR+ HER2-negative breast cancer (BC)
2026 · J. Chien, R. M. Mukhtar, et al. · Clinical Cancer Research · 1
Abstract PS5-08-28: Phase I pilot of pegylated liposomal doxorubicin, CD40 agonist antibody CDX-1140, and Flt3 ligand CDX-301 in advanced HER2-negative breast cancer
2026 · S. M. Reddy, C. A. Santa-Maria, et al. · Clinical Cancer Research
Abstract PS3-10-11: Feasibility of Telemonitoring of Personalized Circadian Rhythms in Patients with Early-Stage HR-Positive Breast Cancer Receiving Endocrine Therapy
2026 · S. Poland, N. Chen, et al. · Clinical Cancer Research
Abstract PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial
2026 · P. R. POHLMANN, N. Chen, et al. · Clinical Cancer Research
Abstract PS5-12-19: Pre-ispy trial: a phase i/ib oncology platform program (pre-i-spy-p1) nct05868226
2026 · P. R. POHLMANN, D. A. Potter, et al. · Clinical Cancer Research
PS5-09-27: A phase i/ii single-arm trial of azenosertib (zn-c3) combined with carboplatin and pembrolizumab in patients with metastatic triple-negative breast cancer (zap-it)
2026 · F. Lynce, N. Tayob, et al. · Clinical Cancer Research
Abstract PS3-12-10: Enhancing responses to trastuzumab deruxtecan using tucatinib in HER2-negative breast cancer
2026 · D. S. Peiffer, N. Thompson, et al. · Clinical Cancer Research
Abstract PS3-07-10: Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot
2026 · K. V. Giridhar, M. P. Goetz, et al. · Clinical Cancer Research
Works count: 8
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type